关于动脉硬化性心脏病中MER-29的说明。 - Suppr

Suppr

超能文献

Note on MER-29 in arteriosclerotic heart disease.

作者信息

CORCORAN A C, ZIMMERMAN H A, CUTURELLI R

出版信息

Prog Cardiovasc Dis. 1960 May;2:576-7. doi: 10.1016/s0033-0620(60)80036-9.

DOI:10.1016/s0033-0620(60)80036-9

PMID:13811921

Abstract

摘要

相似文献

Note on MER-29 in arteriosclerotic heart disease.

Prog Cardiovasc Dis. 1960 May;2:576-7. doi: 10.1016/s0033-0620(60)80036-9.

The cholesterol lowering effects of triparanol (MER-29) in subjects with and without coronary artery disease.

Prog Cardiovasc Dis. 1960 May;2:637-44. doi: 10.1016/s0033-0620(60)80047-3.

A clinical study of triparanol (MER-29).

Am J Cardiol. 1960 Aug;6:246-51. doi: 10.1016/0002-9149(60)90311-8.

Prognostic significance of triparanol (MER-29).

Prog Cardiovasc Dis. 1960 May;2:618-21. doi: 10.1016/s0033-0620(60)80043-6.

Coronary atherosclerosis status of MER-29 (triparanol).

Am Heart J. 1961 Apr;61:431-5. doi: 10.1016/0002-8703(61)90541-5.

Triparanol therapy in coronary heart disease. A preliminary report.

Md State Med J. 1962 Apr;11:178-81.

The effects of triparanol (MER-29) in subjects with and without coronary artery disease.

JAMA. 1960 Sep 3;174:5-12. doi: 10.1001/jama.1960.03030010007002.

Triparanol and nicotinic acid in the management of hypercholesterolaemia.

Australas Ann Med. 1962 Feb;11:29-33. doi: 10.1111/imj.1962.11.1.29.

Effect of MER-29 on the pain experience and the electrocardiographic response to standard exercise in patients with coronary artery disease.

Prog Cardiovasc Dis. 1960 May;2:578-85. doi: 10.1016/s0033-0620(60)80037-0.

Hypocholesterolemic effect of tetraiodothyroformic acid on brittle coronary patients.

Arch Intern Med. 1960 Dec;106:809-15. doi: 10.1001/archinte.1960.03820060061006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Note on MER-29 in arteriosclerotic heart disease.

作者信息

CORCORAN A C, ZIMMERMAN H A, CUTURELLI R

出版信息

Prog Cardiovasc Dis. 1960 May;2:576-7. doi: 10.1016/s0033-0620(60)80036-9.

DOI:10.1016/s0033-0620(60)80036-9

PMID:13811921

Abstract

摘要

相似文献

Note on MER-29 in arteriosclerotic heart disease.

Prog Cardiovasc Dis. 1960 May;2:576-7. doi: 10.1016/s0033-0620(60)80036-9.

The cholesterol lowering effects of triparanol (MER-29) in subjects with and without coronary artery disease.

Prog Cardiovasc Dis. 1960 May;2:637-44. doi: 10.1016/s0033-0620(60)80047-3.

A clinical study of triparanol (MER-29).

Am J Cardiol. 1960 Aug;6:246-51. doi: 10.1016/0002-9149(60)90311-8.

Prognostic significance of triparanol (MER-29).

Prog Cardiovasc Dis. 1960 May;2:618-21. doi: 10.1016/s0033-0620(60)80043-6.

Coronary atherosclerosis status of MER-29 (triparanol).

Am Heart J. 1961 Apr;61:431-5. doi: 10.1016/0002-8703(61)90541-5.

Triparanol therapy in coronary heart disease. A preliminary report.

Md State Med J. 1962 Apr;11:178-81.

The effects of triparanol (MER-29) in subjects with and without coronary artery disease.

JAMA. 1960 Sep 3;174:5-12. doi: 10.1001/jama.1960.03030010007002.

Triparanol and nicotinic acid in the management of hypercholesterolaemia.

Australas Ann Med. 1962 Feb;11:29-33. doi: 10.1111/imj.1962.11.1.29.

Effect of MER-29 on the pain experience and the electrocardiographic response to standard exercise in patients with coronary artery disease.

Prog Cardiovasc Dis. 1960 May;2:578-85. doi: 10.1016/s0033-0620(60)80037-0.

Hypocholesterolemic effect of tetraiodothyroformic acid on brittle coronary patients.

Arch Intern Med. 1960 Dec;106:809-15. doi: 10.1001/archinte.1960.03820060061006.